Clinomics Inc. (KOSDAQ:352770)

South Korea flag South Korea · Delayed Price · Currency is KRW
625.00
+144.00 (29.94%)
Feb 20, 2025, 9:00 AM KST
-73.29%
Market Cap 22.45B
Revenue (ttm) 8.25B
Net Income (ttm) -34.32B
Shares Out 38.45M
EPS (ttm) -1,012.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,180,482
Average Volume 5,068,105
Open 506.00
Previous Close 481.00
Day's Range 506.00 - 625.00
52-Week Range 283.00 - 2,660.00
Beta 1.18
RSI 61.07
Earnings Date Mar 20, 2025

About Clinomics

Clinomics Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company’s liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (CTCs), cell free DNA, and EV (exosome) derived from cancer tissues; Cancer-PRIME, a cancer gene analysis service for analyzing results related to prec... [Read more]

Industry Medical Laboratories
Founded 2011
Employees 73
Stock Exchange KOSDAQ
Ticker Symbol 352770
Full Company Profile

Financial Performance

In 2023, Clinomics's revenue was 11.41 billion, a decrease of -50.58% compared to the previous year's 23.08 billion. Losses were -42.26 billion, 315.2% more than in 2022.

Financial Statements

News

There is no news available yet.